top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S....
56 minutes ago
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy...
Apr 2
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT ® in treating pancreatic cancer showing high disease control rate,...
Mar 13
Alpha Tau to Participate in March Investor Conferences
JERUSALEM, February 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Feb 27
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Feb 24
bottom of page